CADL vs. REPL, URGN, LIFE, IOBT, ALGS, IMTX, PROK, MESO, RLAY, and PRME
Should you be buying Candel Therapeutics stock or one of its competitors? The main competitors of Candel Therapeutics include Replimune Group (REPL), UroGen Pharma (URGN), aTyr Pharma (LIFE), IO Biotech (IOBT), Aligos Therapeutics (ALGS), Immatics (IMTX), ProKidney (PROK), Mesoblast (MESO), Relay Therapeutics (RLAY), and Prime Medicine (PRME). These companies are all part of the "medical" sector.
Replimune Group (NASDAQ:REPL) and Candel Therapeutics (NASDAQ:CADL) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, community ranking, dividends, analyst recommendations, earnings, media sentiment, institutional ownership and profitability.
In the previous week, Replimune Group and Replimune Group both had 3 articles in the media. Candel Therapeutics' average media sentiment score of 1.33 beat Replimune Group's score of 0.77 indicating that Replimune Group is being referred to more favorably in the media.
Replimune Group currently has a consensus price target of $37.67, indicating a potential upside of 614.74%. Candel Therapeutics has a consensus price target of $11.00, indicating a potential upside of 23.60%. Given Candel Therapeutics' higher probable upside, equities research analysts clearly believe Replimune Group is more favorable than Candel Therapeutics.
Replimune Group has a beta of 1.25, indicating that its stock price is 25% more volatile than the S&P 500. Comparatively, Candel Therapeutics has a beta of -0.94, indicating that its stock price is 194% less volatile than the S&P 500.
Candel Therapeutics' return on equity of -48.62% beat Replimune Group's return on equity.
Candel Therapeutics has higher revenue and earnings than Replimune Group. Candel Therapeutics is trading at a lower price-to-earnings ratio than Replimune Group, indicating that it is currently the more affordable of the two stocks.
92.5% of Replimune Group shares are held by institutional investors. Comparatively, 13.9% of Candel Therapeutics shares are held by institutional investors. 20.6% of Replimune Group shares are held by insiders. Comparatively, 44.6% of Candel Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Replimune Group received 144 more outperform votes than Candel Therapeutics when rated by MarketBeat users. Likewise, 61.54% of users gave Replimune Group an outperform vote while only 50.00% of users gave Candel Therapeutics an outperform vote.
Summary
Replimune Group beats Candel Therapeutics on 10 of the 14 factors compared between the two stocks.
Get Candel Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CADL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CADL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Candel Therapeutics Competitors List
Related Companies and Tools
